MX2018006773A - Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina. - Google Patents
Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.Info
- Publication number
- MX2018006773A MX2018006773A MX2018006773A MX2018006773A MX2018006773A MX 2018006773 A MX2018006773 A MX 2018006773A MX 2018006773 A MX2018006773 A MX 2018006773A MX 2018006773 A MX2018006773 A MX 2018006773A MX 2018006773 A MX2018006773 A MX 2018006773A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- lamivudine
- doravirin
- tenofovir disoproxil
- disoproxil fumarate
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229960001627 lamivudine Drugs 0.000 title abstract 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 title abstract 2
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 title abstract 2
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title abstract 2
- ZIAOVIPSKUPPQW-UHFFFAOYSA-N 3-chloro-5-[1-[(4-methyl-5-oxo-1h-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile Chemical compound N1C(=O)N(C)C(CN2C(C(OC=3C=C(C=C(Cl)C=3)C#N)=C(C=C2)C(F)(F)F)=O)=N1 ZIAOVIPSKUPPQW-UHFFFAOYSA-N 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 229950003141 doravirine Drugs 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas que comprenden doravirina, tenofovir disoproxil fumarato y lamivudina. Estas composiciones son útiles para el tratamiento de la infección por VIH. Asimismo se describen procesos para preparar dichas composiciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562261953P | 2015-12-02 | 2015-12-02 | |
| PCT/US2016/063894 WO2017095761A1 (en) | 2015-12-02 | 2016-11-29 | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018006773A true MX2018006773A (es) | 2018-08-01 |
| MX374931B MX374931B (es) | 2025-03-06 |
Family
ID=58797976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006773A MX374931B (es) | 2015-12-02 | 2016-11-29 | Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10603282B2 (es) |
| EP (3) | EP4424373B1 (es) |
| JP (1) | JP6866374B2 (es) |
| KR (1) | KR102774942B1 (es) |
| CN (1) | CN108367008B (es) |
| AU (1) | AU2016361612B2 (es) |
| BR (1) | BR112018011085B1 (es) |
| CA (1) | CA3006192C (es) |
| CY (1) | CY1124748T1 (es) |
| DK (1) | DK3383397T3 (es) |
| ES (1) | ES2895951T3 (es) |
| HR (1) | HRP20211687T1 (es) |
| HU (1) | HUE056978T2 (es) |
| LT (1) | LT3383397T (es) |
| MX (1) | MX374931B (es) |
| PL (1) | PL3383397T3 (es) |
| PT (1) | PT3383397T (es) |
| RS (1) | RS62466B1 (es) |
| RU (1) | RU2736941C2 (es) |
| SI (1) | SI3383397T1 (es) |
| WO (1) | WO2017095761A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3383397T3 (da) * | 2015-12-02 | 2021-11-08 | Merck Sharp & Dohme | Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin |
| CN110769856A (zh) * | 2017-04-18 | 2020-02-07 | 希普拉有限公司 | 用于治疗逆转录病毒感染的组合疗法 |
| BR112020015759A2 (pt) * | 2018-02-02 | 2020-12-08 | Genentech, Inc. | Composto farmacêutico, sais do mesmo, formulações do mesmo e métodos para produzir e usar o mesmo |
| CN113288905A (zh) * | 2021-07-14 | 2021-08-24 | 石家庄龙泽制药股份有限公司 | 含多替拉韦钠、拉米夫定和富马酸诺福韦酯的药物组合物 |
| CN115554248B (zh) * | 2022-08-25 | 2023-09-22 | 平阳润德医院有限公司 | 一种治疗小儿巨细胞病毒感染性肝炎的肠溶型中药制剂及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| DE602006015721D1 (de) * | 2005-12-14 | 2010-09-02 | Cipla Ltd | Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit |
| JP2010529196A (ja) * | 2007-06-12 | 2010-08-26 | コンサート ファーマシューティカルズ インコーポレイテッド | アザペプチド誘導体 |
| WO2009106960A2 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable compositions of lamivudine, tenofovir and efavirenz |
| EP2295038B1 (en) | 2009-09-11 | 2013-05-29 | AiCuris GmbH & Co. KG | Solid dispersion comprising an anti-HIV agent |
| RS54017B1 (sr) | 2010-03-30 | 2015-10-30 | Merck Canada Inc. | Ne-nukleozidni inhibitori reverzne transkriptaze |
| WO2012164241A1 (en) * | 2011-05-30 | 2012-12-06 | Cipla Limited | Pharmaceutical antiretroviral composition |
| EP2958563A2 (en) | 2013-02-20 | 2015-12-30 | AbbVie Inc. | Tablet dosage form comprising ritonavir and lopinavir |
| MX375870B (es) * | 2013-11-22 | 2025-03-07 | Merck Sharp & Dohme Llc | Composicion de un inhibidor de la transcriptasa inversa sin nucleosido. |
| WO2015179448A1 (en) * | 2014-05-21 | 2015-11-26 | Gilead Sciences, Inc. | Therapeutic compounds |
| DK3383397T3 (da) * | 2015-12-02 | 2021-11-08 | Merck Sharp & Dohme | Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin |
-
2016
- 2016-11-29 DK DK16871332.9T patent/DK3383397T3/da active
- 2016-11-29 HU HUE16871332A patent/HUE056978T2/hu unknown
- 2016-11-29 EP EP24183101.5A patent/EP4424373B1/en active Active
- 2016-11-29 MX MX2018006773A patent/MX374931B/es active IP Right Grant
- 2016-11-29 CN CN201680070227.0A patent/CN108367008B/zh active Active
- 2016-11-29 PL PL16871332T patent/PL3383397T3/pl unknown
- 2016-11-29 BR BR112018011085-0A patent/BR112018011085B1/pt active IP Right Grant
- 2016-11-29 PT PT168713329T patent/PT3383397T/pt unknown
- 2016-11-29 JP JP2018528299A patent/JP6866374B2/ja active Active
- 2016-11-29 HR HRP20211687TT patent/HRP20211687T1/hr unknown
- 2016-11-29 EP EP16871332.9A patent/EP3383397B1/en active Active
- 2016-11-29 KR KR1020187015257A patent/KR102774942B1/ko active Active
- 2016-11-29 EP EP21197509.9A patent/EP3960163A1/en not_active Withdrawn
- 2016-11-29 ES ES16871332T patent/ES2895951T3/es active Active
- 2016-11-29 WO PCT/US2016/063894 patent/WO2017095761A1/en not_active Ceased
- 2016-11-29 CA CA3006192A patent/CA3006192C/en active Active
- 2016-11-29 US US15/780,142 patent/US10603282B2/en active Active
- 2016-11-29 RS RS20211287A patent/RS62466B1/sr unknown
- 2016-11-29 AU AU2016361612A patent/AU2016361612B2/en active Active
- 2016-11-29 SI SI201631373T patent/SI3383397T1/sl unknown
- 2016-11-29 LT LTEPPCT/US2016/063894T patent/LT3383397T/lt unknown
- 2016-11-29 RU RU2018123620A patent/RU2736941C2/ru active
-
2020
- 2020-02-14 US US16/791,398 patent/US10842751B2/en active Active
-
2021
- 2021-11-19 CY CY20211101008T patent/CY1124748T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19078196A (es) | Composiciones terapéuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato | |
| MX2019009361A (es) | Composiciones y metodos para el tratamiento de hemoglobinopatias. | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| MX2017008720A (es) | Derivados y metodos para tratamiento de las infecciones por hepatitis b. | |
| CU20170089A7 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| UY36705A (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| MX358099B (es) | Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos. | |
| MX2016009625A (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
| MX374443B (es) | Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
| MX374794B (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| BR112018007395A2 (pt) | 2,4-di-hidróxi-nicotinamidas como agonistas de apj | |
| BR112018068341A2 (pt) | 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj | |
| UY35993A (es) | Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina | |
| MX2018006773A (es) | Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina. | |
| MA45381A (fr) | Formulation de vaccin contre le vih | |
| IN2014MN01907A (es) | ||
| DOP2017000086A (es) | Composiciones farmacéuticas de acción prolongada | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| BR112017019850A2 (pt) | ?processo melhorado para a preparação de apremilast? | |
| MX369857B (es) | Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6). | |
| IN2014MU00916A (es) | ||
| BR112016028083A2 (pt) | Composição oral farmacêutica de isotretinoina e seu processo de preparação | |
| CY1123449T1 (el) | Mini δισκια μελατονινης και μεθοδος παρασκευης αυτων | |
| CO2017005767A2 (es) | Composiciones de acción prolongada de combinación y procedimientos para hepatitis c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |